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Abstract
This work evaluated a commercial fallback planning workflow designed to provide cross-platform treatment planning and delivery.
A total of 27 helical tomotherapy intensity-modulated radiotherapy plans covering 4 anatomical sites were selected, including
7 brain, 5 unilateral head and neck, 5 bilateral head and neck, 5 pelvis, and 5 prostate cases. All helical tomotherapy plans were
converted to 7-field/9-field intensity-modulated radiotherapy and volumetric-modulated radiotherapy plans through fallback
dose-mimicking algorithm using a 6-MV beam model. The planning target volume (PTV) coverage (D1, D99, and homogeneity
index) and organs at risk dose constraints were evaluated and compared. Overall, all 3 techniques resulted in relatively inferior
target dose coverage compared to helical tomotherapy plans, with higher homogeneity index and maximum dose. The organs at
risk dose ratio of fallback to helical tomotherapy plans covered a wide spectrum, from 0.87 to 1.11 on average for all sites, with
fallback plans being superior for brain, pelvis, and prostate sites. The quality of fallback plans depends on the delivery technique,
field numbers, and angles, as well as user selection of structures for organs at risk. In actual clinical scenario, fallback plans would
typically be needed for 1 to 5 fractions of a treatment course in the event of machine breakdown. Our results suggested that <1%
dose variance can be introduced in target coverage and/or organs at risk from fallback plans. The presented clinical workflow
showed that the fallback plan generation typically takes 10 to 20 minutes per case. Fallback planning provides an expeditious and
effective strategy for transferring patients cross platforms, and minimizing the untold risk of a patient missing treatment(s).
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Introduction
Modern radiotherapy treatment planning and delivery provide
high conformity in target coverage and tissue sparing for
adjacent organs at risk (OARs), thus improving tumor control
probability and decreasing morbidity.1,2 The 2 radiotherapy
treatment modalities that can achieve advanced plan complex-
ity include conventional L-shape linear accelerators, that is,
Elekta (Stockholm, Sweden) and Varian (Palo Alto, Califor-
nia), and O-shape linear accelerators, that is, Tomotherapy
(Accuray, Sunnyvale, California), and Halcyon (Varian, Palo
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Alto, California). The helical tomotherapy (HT) Hi-Art model
combines a 6-MV linear accelerator and a helical Mega-voltage
computed tomography (MVCT) scanner for delivering highly
conformal intensity modulated helical beams. The technical
details and clinical efficacy of HT have been well described
in medical physics literature.3-5 The TomoEDGE (Accuray,
Sunnyvale, California) series features dynamic jaws that open
and close when tracking the target boundary as it enters and
exits the treatment field.6-10 This feature reduces the dose
penumbra along the superior and inferior direction, thus
improves conformity.6-10 In the helical delivery, dose delivered
to the target volume depends on the dose rate, multi-leaf col-
limator (MLC) delivery sequence, pitch, speed of gantry rota-
tion, and total number of rotations.11 Tomotherapy has
demonstrated its ability to create high-quality plans that are
comparable and/or superior to L-shaped linacs that deliver
multifield intensity-modulated radiotherapy (IMRT) or
volumetric-modulated radiotherapy (VMAT) plans for vari-
ous cancer sites.11-14 Tomotherapy systems have significantly
improved their reliability and reduced system downtime since
their early installations. However, it remains a concern to
those clinics that do not have twined systems to account for
any downtime. At our institution, we treat about one-third of
our patients on 1 Tomotherapy HDA (TM) unit, mostly using
the helical IMRT delivery with the dynamic jaw feature. In an
unintended machine down event, it is highly desired to have
backup plans to continue those patients’ treatment on other L-
shape linacs in the department. Treatment continuity is crucial
for radiotherapy patients, especially for those with concurrent
chemotherapy regimens, to avoid significant loss in local
tumor control.15-18
Manual creation of a conventional backup plan for every
tomotherapy plan might double dosimetrists’ planning time
and physicians’ reviewing time. In response to the need of
autoplanning, RayStation treatment planning system (Ray-
Search Laboratories AB, Stockholm, Sweden) has released its
automated planning function, with the name fallback (FB)
planning. The FB converts a given reference plan to plans that
can be delivered on a different platform using dose-mimicking
algorithm, that is, converting from an HT plan to a multifield
IMRT or VMAT plan. This commercial software allows for
automated creation and optimization of coplanar/noncoplanar
3D conformal radiotherapy (3DCRT), IMRT, and VMAT FB
plans from reference plans’ dose–volume histogram (DVH) of
any modality.19 For clinics with only 1 tomotherapy unit, this
solution can serve as a clinical treatment alternative when the
tomotherapy unit is unavailable. So far there has been only 1
publication on the FB planning, which only evaluated clinical
performance for converting HT plans to 3DCRT for lung and
9-field IMRT plans for lung, head and neck (HN), and pros-
tate site.20 Herein, we provide a more comprehensive evalua-
tion of FB planning in generating multiple plan options,
including 7-field IMRT, 9-field IMRT, and VMAT, for brain,
HN, prostate, and pelvis patients. The goals of this study are to
evaluate FB plan quality and its clinical workflow efficiency
in the event of machine breakdown.
Methods
Plan Selection
From our patient database, a total of 27 previously treated HT
patients were identified for this internal review board (IRB)
(protocol no. CCRO050) approved retrospective study. The
study included 7 brain, 5 simple HN, 5 complex HN, 5 pelvis,
and 5 prostate cases. For 7 brain cases, disease sites included
frontal, occipital, parietal lobes, and ventricles, with different
levels of prescription dose varying between 25 and 55.8 Gy.
For HN cases, 5 simple ones were unilateral and 5 complex
ones were bilateral simultaneous integrated boost (SIB) tar-
gets. For simple HN plans, the planning target volume (PTV)
was prescribed to receive at least 95% of 60 Gy in 30 frac-
tions/66 Gy in 33 fractions. For SIB complex plans, the high-
est PTV dose was 70 Gy in 33 fractions. The pelvis cases were
prescribed to at least 95% of the PTV receiving 45 Gy in 25
fractions. Among the 5 pelvis plans, 4 were considered com-
plex with the para-aortic lymph nodes involvement. Among
the 5 prostate cases, 2 were prescribed such that at least 95%
of the PTV receives 70 Gy in 28 fractions, and the other 3
cases (intermediate/high risk) with proximal seminal vesicles
involvement were treated to a total dose of 79.2 Gy in 44
fractions.
Fallback Planning Protocol
The predefined protocols are beam energy/treatment type spe-
cific and include information on beam angles, couch, and col-
limator angles. In this study, 2-arc VMAT and 7- and 9-field
IMRT protocols were generated for FB plan creation. All
VMAT plans were optimized further with 60 iterations in Rays-
tation, while no additional optimization was made for FB
IMRT plans. The dose-mimicking algorithm used for FB plan
optimization uses an objective function to minimize the differ-
ence between the reference plan and FB plans generated for
another treatment platform in terms of their DVH curves. Unit
weight is given to the objective functions for OARs and targets
are weighted based on user-defined target priority.20 In our
study, a target weight priority of 100 was used for all FB plans.
Clinical Workflow
Steps involved in a clinical implementation of an FB system are
explained as follows: (1) Technique-specific protocols have
been established at the time of commissioning, as explained
in “Fallback Planning Protocol” section; (2) patients needing
FB plans are identified by the physician at the time of treatment
start; (3) on the day that FB plans are needed, as cases are
prioritized, dosimetrists create FB plans and request physi-
cians’ evaluation and approval; (4) approved plans are then
transferred to Record and Verify (R&V) system, and second
checked by a physicist per departmental policies and proce-
dures; and (5) patient-specific quality assurance (QA) has to
be performed for plan dose verification on the same day of the
first fraction being delivered. Finally, the prescription is
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updated to account for the fractions delivered via FB plans
before proceeding with the rest of the treatment.
Figure 1 depicted the timeline of generating an FB plan on
the day when it is needed. DICOM files for CT, structures, and
dose need to be transferred from HT to Raystation TPS. Plan
preparation takes approximately 2 minutes for defining CT-
density table, cleaning region of interest (ROI) types, creating
external ROI, and inserting couch. Fallback plan creation based
on the existing protocol takes approximately 5 minutes for
IMRT plans and 10 to 15 minutes for VMAT plans, which
require extra 40 to 60 iterations to achieve desired dose distri-
bution. The overall plan creation time is 10 to 20 minutes.
Depending on the planning workload or preference, an alterna-
tive workflow is to generate FB plans within a reasonable time-
line after the original plans are done, that is, 1 week after
treatment starts, in order to further reduce plan preparation time
on the day of machine down and improve efficiency.
Dosimetric Analysis
Plans are evaluated quantitatively for their dosimetric perfor-
mance. For PTV coverage, the ratio of D99 to prescription dose
DRx, D1 to DRx, and homogeneity index (HI), are compared.
The HI analyzes the uniformity of dose distribution in the target
volume and is defined as




where D2 and D98 are the dose to 2% and 98% of the PTV
volume, respectively.
For the OAR avoidance comparisons, max-point (Dmax) or
mean-point doses (Dmean) are evaluated when applicable. For
the pelvis plans, the OAR doses are evaluated using V45: V45
<80% (bladder), V45 <80% (rectum), and V45 <50 cc (small
bowel), where VD is the percentage volume receiving a dose of
at least D Gy. Prostate plans use mean point dose (Dmean) for
the penile bulb, V50 <40% for bladder, and V40 <50% for
rectum. Final comparison tables for OARs are made showing
ratios of dose points obtained from FB plans with respect to the
reference plan (HT).
Results and Discussion
The dose mimicked plans are generated in the context of repla-
cing entire treatment fractions and compared against their cor-
responding original HT plans for both PTV coverage and OAR
avoidances. All plans studied here are physician-approved
plans. The average values of HI, D99/DRX, and D1/DRX for
brain, HN simple/complex, and pelvis/prostate plans in terms
of the PTV coverage are listed in Table 1. For brain cases, all 3
FB plan techniques are comparable in terms of the PTV cov-
erage, with slightly higher HI values compared to HT plans.
For HN simple cases, although HT plans still show superior
target coverage, the FB plans are acceptable with VMAT and
9-field IMRT demonstrating better PTV coverage conformity
compared to 7-field IMRT plans. For the complex HN plans, all
Figure 1. Flow diagram depicting the fallback plan creation and execution at our clinic. The approximate time taken during each step is
illustrated.
Table 1. Planning target volume (PTV) Coverage Comparisons of the
VMAT and IMRT Plans Versus HT Plans.
Parameters HT VMAT 7-Field IMRT 9-Field IMRT
Brain
HI 3.3 4.2 4.3 4.1
D99/DRx 98.4% 98.0% 97.8% 97.9%
D1/DRx 102.7% 103.5% 102.1% 103.3%
HN Simple
HI 2.5 5.7 6.3 5.9
D99/DRx 98.8% 100.6% 100.3% 100.5%
D1/DRx 103.2% 107.6% 108.0% 107.7%
HN Complex
HI 4.8 8.4 8.5 8.2
D99/DRx 98.1% 97.8% 97.6% 97.9%
D1/DRx 103.9% 107.6% 107.6% 107.5%
Pelvis
HI 4.4 6.3 6.3 6.1
D99/DRx 97.8% 97.5% 97.5% 97.5%
D1/DRx 103.4% 105.4% 105.3% 105.1%
Prostate
HI 4.7 5.7 5.4 5.7
D99/DRx 97.4% 97.2% 97.0% 97.0%
D1/DRx 103.8% 104.5% 104.0% 104.3%
Abbreviations: HI, homogeneity index; HN, head and neck; HT, helical
tomotherapy; IMRT, Intensity Modulated Radiotherapy; VMRT, Volumetric
Modulated Radiotherapy.
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3 FB techniques are comparable, with slightly inferior values to
HT plans. Similar results are also seen in pelvis and prostate
cases. PTV coverage metrics for individual case in terms of HI,
D99/DRX, and D1/DRX for brain, HN, and pelvis/prostate plans
are presented in Figures 2 to 4. Each HT plan (diamond) has its
corresponding FB plans including VMAT (square), 7-field (tri-
angle), and 9-field IMRT (circle) techniques. The HI, D99/DRX,
and D1/DRX values are plotted in a scale of 0 to 12, 90% to
110%, and 90% to 110%, respectively. For brain cases (Figure
2), HI values (panel A) of the 3 FB techniques are slightly
higher than the values of HT plans, residing in the range of 2
to 7. TheD99/DRX andD1/DRX values (panel B and C) of the FB
plans in each case are mostly overlapping with those of the HT
plans. For simple/complex HN cases (Figure 3), HI values
(panel A) cover a wider range, with most cases <10 for all
FB plan options, except for 1 complex case. The D99/DRX val-
ues (panel B) of all 3 FB options are0.2% to 1.6% higher than
the HT plan, while the D1/DRX values (panel C) are 3.5% to
4.3% higher than the HT plans. For prostate and pelvis cases
(Figure 4), HI values (panel A) of HT plans are averaged at 4.5
with a range of 1.6 to 9.8, while FB plans are average at 6.0
with a range of 2.5 to 10.7. Comparable values are seen in D99/
DRX and D1/DRX.
The OAR dose constraints for all HT treatments depend on
the complexity of the plan and strictly follow the guidelines per
our physicians. Dose constraints for brain treatment are applied
to various OARs, including left and right lens/eye/optic nerve/
cochlea, optic chiasm, and brain stem during plan optimization.
Table 2 listed the OAR dose comparison ratios of VMAT/HT,
7-field IMRT/HT, and 9-field IMRT/HT for brain cases, in
terms of Davg and Dmax for 15 structures. Overall, VMAT
shows on average 11% (range: 13% to 36%) higher dose
Figure 2. Planning target volume (PTV) coverage of the brain fallback
plans compared to the helical tomotherapy (HT) plans. The homoge-
neity index (HI), D99/DRX, and D1/DRX values are shown in panel (A),
(B), and (C), respectively.
Figure 3. Planning target volume (PTV) coverage of the head and
neck (HN) fallback plans compared to the helical tomotherapy (HT)
plans. The homogeneity index (HI), D99/DRX, and D1/DRX values are
shown in panel (A), (B), and (C), respectively.
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compared to HT for those 15 OARs, while 7-field IMRT and
9-field IMRT show on average 13% (range: 23% to 1%) and
10% (range: 21% to 1%) lower dose compared to HT. The
OAR dose comparisons for HN simple/complex plans are listed
in Table 3. The dose constraints are applied to brainstem, cord,
larynx, upper esophagus, left and right parotid during plan
optimization. Results show that for simple HN cases, the 3
FB plan options provided OAR doses comparable to the
original HT plans, with VMAT plans being slightly superior
(average:3%; range:13% to 5%) to HT plans. For complex
HN cases, only VMAT plans are equivalent to HT plans, with
an average dose ratio of 1.01 and a range of 0.92 to 1.09. The
other 2 IMRT plans are shown slightly inferior to HT plans,
with the same dose ratio of 1.08 and a range of 0.98 to 1.20.
The OAR dose ratios of FB plans versus HT plans for pelvis/
prostate are provided in Table 4. Compared to HT plans, all
3 options show lower OAR doses, that is, VMAT11% to 0%,
7-field IMRT 9% to 1%, and 9-field IMRT 8% to 2%. For
prostate, typical dose constraints followed the RTOG 0815
protocol and the institution-specific guidelines, including Dave
<52 Gy for penile bulb, V50Gy <40% for bladder, and V40Gy
<50% for rectum. Results show superior dose on the OARs in
FB plans compared to HT plans, with VMAT ranging from
12% to 1%, 7-field IMRT 15% to 1%, and 9-field IMRT
19% to 2%.
Note that the plan comparisons are performed for all frac-
tions of the original HT and their FB plans. For the actual
clinical scenario, we experienced so far, the maximum frac-
tions that we had to supplement with the FB plan was 2. Under
this circumstance, the overall dosimetric differences between
all 3 FB plans and original HT plans are considered negligible
and not clinically significant. For plan delivery verification,
patient specific QA was performed on all plans included in this
study using Sun Nuclear’s ArcCHECK or MapCHECK 2
devices. All QA plans achieved >95% pass rate using the
3%/3 mm g analysis criteria.
In this study, 2-arc VMAT, 7-, and 9-field IMRT plans were
generated for each HT plan studied. Once the protocol is cre-
ated, all FB plans can be generated within 10 to 20 minutes
depending on the plan type, using a dose-mimicking algorithm
based on the DVH imported from the original HT plan. As for
physician’s evaluation and plan approval, it varies significantly
depending on physician’s availability. In a rare scenario of a
machine breakdown in our center, most physicians would make
these plans first priority. Therefore, plan evaluation and
approval time is roughly 30 minutes. As we mentioned
Figure 4. Planning target volume (PTV) coverage of the pelvis/
prostate fallback plans compared to the helical tomotherapy (HT)
plans. The homogeneity index (HI), D99/DRX, and D1/DRX values are
shown in panel (A), (B), and (C), respectively.
Table 2. OAR Dose Comparisons of VMAT and IMRT Plans Versus









Brain (Davg) 1.36 0.98 0.99
Brainstem (Dmax) 1.13 0.85 0.85
Hypothalamus (Dmax) 1.19 0.94 0.94
Left cochlea (Dmax) 1.14 0.80 0.83
Left eye (Dmax) 1.11 0.85 0.86
Left lens (Dmax) 1.15 0.91 0.95
Left optic nerve (Dmax) 1.11 0.92 0.92
Optic chiasm (Dmax) 1.15 0.91 0.87
Pituitary stalk and gland (Dmax) 1.01 0.88 0.84
Right cochlea (Dmax) 1.12 0.87 0.85
Right eye (Dmax) 1.11 0.77 1.01
Right lens (Dmax) 1.13 0.82 0.98
Right optic nerve (Dmax) 1.11 0.82 0.83
Skull (Dmax) 1.01 1.01 1.00
Spinal cord (Dmax) 0.87 0.79 0.79
Average 1.11 0.87 0.90
Standard deviation 0.10 0.07 0.07
Abbreviations: HT, helical tomotherapy; IMRT, Intensity Modulated Radio-
therapy; OAR, organs at risk; VMRT, Volumetric Modulated Radiotherapy.
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previously, FB plan QA is performed after the first treatment
fraction; therefore, it is not taken into account in the pressuring
timeline of FB plan preparation. In terms of the target cover-
age, no clinically significant differences were observed within
3 FB options, with all of them being slightly inferior to the HT
plans considering the entire prescribed fractions. For brain
OARs, VMAT gives on average 11% higher doses compared
to HT, while both IMRT techniques give on average 9% lower
doses. For HN OARs, all 3 techniques are equivalent to the
HT plans for simple HN cases, while for complex cases, both
IMRT techniques have on average 8% higher doses compared
to HT. For both pelvis and prostate cases, all 3 techniques
result in on average 5% and 8% lower doses compared to
HT, respectively. Zhang et al also studied the performance
of 9-field IMRT for HN and prostate cases and presented
similar findings with inferior target coverage and comparable
OAR dose sparing compared to HT.20 Our study further
explored the performance of 7-field IMRT and VMAT for all
4 anatomical sites, which provided a more practical solution
to the clinic considering much shorter treatment delivery time
with 7-field IMRT or VMAT.
The FB planning module provides the automated plan opti-
mization and creation ability for efficiently generating con-
ventional linac-based plans mimicking the dose distribution
from the initial HT plans. The dose mimicking optimization
process seeks to create a similar DVH of an HT plan with an
alternative treatment technique (ie, IMRT or VMAT) by
maintaining target conformity and penalizing dose falloff out-
side the target. Overall, for all 4 anatomical sites, FB plans are
inferior in target coverage but within+10% for OAR avoid-
ance in the context of the entire prescribed treatment. Con-
sidering the actual need for these FB plans is mostly <10% of
the prescribed fractions, the dose deviation caused by supple-
menting with the FB fractions should be <1%. When choosing
an FB technique, VMAT is comparable to IMRT plans in
terms of the dose coverage for HN, pelvis, and prostate cases.
Yet VMAT delivery would be faster than IMRT, with the cost
of extra 10 minutes in plan optimization when creating the FB
plan. For brain, no clinically significant dose differences were
observed between 7-field and 9-field IMRT, while VMAT is
inferior in OAR sparing. Therefore, 7-field IMRT may be a
better option than 9-field considering the time efficiency in
plan delivery.
Conclusion
Transferring and mimicking treatment plans across platforms
from an O-shaped linac to an L-shaped linac have been
Table 3. OAR Dose Comparisons of VMAT and IMRT Plans Versus HT Plans for HN Cases.
OAR
HN Simple HN Complex
VMAT/HT 7-Field IMRT/HT 9-Field IMRT/HT VMAT/HT 7-Field IMRT/HT 9-Field IMRT/HT
Parotid_R (Davg) 1.02 1.10 1.05 1.05 1.14 1.14
Parotid_L (Davg) 1.02 1.08 1.03 1.09 1.20 1.15
Larynx (Davg) 0.87 1.02 0.97 1.00 1.05 1.02
Esophagus (Davg) 0.88 0.92 0.95 0.92 0.98 0.99
Brainstem (Dmax) 1.05 1.04 0.98 0.98 1.04 1.09
Cord (Dmax) 0.99 1.05 1.04 1.03 1.08 1.06
Average 0.97 1.03 1.00 1.01 1.08 1.08
Standard deviation 0.08 0.06 0.04 0.06 0.08 0.06
Abbreviations: HN, head and neck; HT, helical tomotherapy; IMRT, Intensity Modulated Radiotherapy; OAR, organs at risk; VMRT, Volumetric Modulated
Radiotherapy.
Table 4. OAR Dose Comparisons of VMAT and IMRT Plans Versus HT Plans for Pelvis and Prostate Cases.
OAR
Pelvis Prostate
VMAT/HT 7-Field IMRT/HT 9-Field IMRT/HT VMAT/HT 7-Field IMRT/HT 9-Field IMRT/HT
Bladder 0.97 0.97 0.96 0.93 0.92 0.95
Rectum 1.00 1.01 1.02 0.99 1.01 1.02
Femur_R 0.92 0.91 0.92 0.91 0.85 0.81
Femur_L 0.89 0.91 0.92 0.93 0.93 0.82
Bowel 0.98 0.98 0.99 – – –
Penile bulb – – – 0.88 0.89 0.91
Average 0.95 0.96 0.96 0.93 0.92 0.90
Standard deviation 0.05 0.04 0.04 0.04 0.06 0.09
Abbreviations: HT, helical tomotherapy; IMRT, Intensity Modulated Radiotherapy; OAR, organs at risk; VMRT, Volumetric Modulated Radiotherapy.
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automated by a commercial program which requires modest
time and effort from planners. Dosimetric evaluation of the
mimicked plans has been performed, which demonstrated that
FB plans are deliverable and clinically comparable to the over-
all treatment plan when utilized as a backup option. The overall
workflow can be a practical and efficient alternative for patient
treatment in the event of machine down. Further efforts are
underway to optimize the quality and flexibility of FB planning
for potential use in a wider array of treatment delivery options
and cross-platform technologies.
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